EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

COST-EFFECTIVENESS OF CEFTRIAXONE-SULBACTAM IN TREATMENT OF NOSOCOMIAL INFECTIONS USING PROBABILISTIC SENSITIVITY ANALYSIS

Vishnu Dutt Sharma, Manu Chaudhary and Manish Taneja*

ABSTRACT

Increasing prevalence of carbapenem resistance in Gram negative bacteria due to excessive and indiscriminate use of carbapenems has forced the medical fraternity to look for better alternatives. One promising solution is to use pharmacodynamically synergistic drugs combination against the resistant pathogen. Recently, a fixed dose combination of ceftriaxone/sulbactam (2/1) (marketed as Elores®) has shown promising response against antibacterial resistance. However, the economic evaluation of Elores in comparison with carbapenem class of drug was not done so far. Therefore, the objective of the present study was to evaluate the cost-effectiveness of Elores and meropenem against hospital acquired infections (HAIs). A retrospective study on patients receiving either Elores or meropenem with/without colistin in management of HAIs was utilized for the cost effective analysis (CEA) study using ‘decision table” as an analytical model. Cost of therapy evaluation included both direct and indirect costs. Effectiveness measures were estimated from drug’s efficacy, adherence tendencies and tolerability in the model. The cost effectiveness ratio (CER) were computed, where Elores treatment was more cost-effective than meropenem treated approach with CER of INR 1132 (USD $ 17.4) per unit of effectiveness measures. The probabilistic sensitivity analysis was then performed to improve the model predictions, and to reduce the uncertainty in the model parameters. In base-case analysis, Elores was superior with an incremental-CER (ICER) of INR 27 at willingness-to-pay (WTP) of INR 200. The model was robust to variations in model input parameters. The study advocated Elores as a cost-effective use of resources and as a carbapenem sparer drug in the management of HAIs.

Keywords: Cost Effectiveness Analysis, Antibacterial Therapy, decision tree analysis, probabilistic sensitivity analysis.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 May 2020 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR MAY ISSUE PUBLISHED

    MAY 2020 Issue has been successfully launched on 1 May 2020.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing